Takeda Pharmaceutical Company Limited(4502) News

The 149th (interim period) Business Report

Semi-annual Securities Report (The semi-annual of 149th Business Term) for The Six-month Period Ended September 30, 2025

Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)

Earnings Report (Kessan Tanshin) for the Six-month Period Ended September 30, 2025 (IFRS, Consolidated)

Takeda Provides Update on Cell Therapy Research

Information About General Reserve and Other Voluntary Reserves

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Statement on Inadvertent Abstract Disclosure for Opevorexton (TAK-861) by World Sleep Congress

Earnings Report (Kessan Tanshin) for the Three-month Period Ended June 30, 2025 (IFRS, Consolidated)

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Corporate Governance Report 2025/07/09

Takeda Completes Disposal of Treasury Shares under the LTIP for Company Group Employees Outside of Japan with Partial Forfeiture

2025 ANNUAL INTEGRATED REPORT

Annual Securities Report From April 1, 2024 to March 31, 2025 (The 148th Fiscal Year)

Takeda Announces New Assignments of Directors

Notice Concerning Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan

Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide

Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2025

Earnings Report (Kessan Tanshin) for the Fiscal Year Ended March 31, 2025 (IFRS, Consolidated)